July 16, 2024
2 min watch
Save
VIDEO: Reduced chemotherapy dose decreases toxicity in acute myeloid leukemia
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Eric Winer, MD, discusses the results of research into acute myeloid leukemia presented at ASCO Annual Meeting.
Winer, a medical oncologist at Dana-Farber Cancer Institute, highlighted a study that examined a new therapy regimen of azacitidine and venetoclax (Venclexta, AbbVie) in patients with acute myeloid leukemia, using only 7 days of each.
“By decreasing the dose of chemotherapy, one of the things that this will allow us to do is sort of decrease the toxicity, decrease the myelosuppression, and further what it will allow is less infections in the long run, especially in a population that's an older population,” Winer said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Winer reports serving on an advisory board for Curis and Takeda.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.